Literature DB >> 17445500

Botulinum toxin in the management of dystonia.

Omar D Cardona-Garcia1, Donald S Higgins, Eric S Molho.   

Abstract

Dystonia is a neurologic disorder that can occur at any age and often results in significant disability. The therapeutic application of botulinum toxin has revolutionized the treatment of this disorder, particularly for the adult-onset focal forms such as cervical dystonia and blepharospasm. The two available commercial preparations, botulinum toxin types A and B, have been shown to be equally efficacious in cervical dystonia and are both reasonable first-line choices for treating other forms of focal dystonia. Preliminary studies have suggested that differences in tolerability and immunogenicity may exist between the two preparations, but this has not been adequately evaluated. Because of high cost, complicated administration, potentially serious side effects, and the risk of developing immunoresistance, this treatment should be administered only by a physician with sufficient background in the diagnosis and treatment of dystonia, to ensure optimal outcomes.

Entities:  

Year:  2007        PMID: 17445500     DOI: 10.1007/bf02938412

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  40 in total

1.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.

Authors:  G-Y R Hsiung; S K Das; R Ranawaya; A-L Lafontaine; O Suchowersky
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

3.  Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.

Authors:  C L Comella; A S Buchman; C M Tanner; N C Brown-Toms; C G Goetz
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

4.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

5.  Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.

Authors:  J Jankovic; C Hunter; B Z Dolimbek; G S Dolimbek; C H Adler; A Brashear; C L Comella; M Gordon; D E Riley; K Sethi; C Singer; M Stacy; D Tarsy; M Z Atassi
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

Review 6.  Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.

Authors:  D D Truong; R Bhidayasiri
Journal:  Eur J Neurol       Date:  2006-02       Impact factor: 6.089

7.  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

Authors:  M F Brin; M F Lew; C H Adler; C L Comella; S A Factor; J Jankovic; C O'Brien; J J Murray; J D Wallace; A Willmer-Hulme; M Koller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

8.  Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.

Authors:  N Bhattacharyya; D Tarsy
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-04

9.  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Authors:  Daniel Truong; Drake D Duane; Joseph Jankovic; Carlos Singer; Lauren C Seeberger; Cynthia L Comella; Mark F Lew; Robert L Rodnitzky; Fabio O Danisi; James P Sutton; P David Charles; Robert A Hauser; Geoffrey L Sheean
Journal:  Mov Disord       Date:  2005-07       Impact factor: 10.338

10.  Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.

Authors:  P Greene; H Shale; S Fahn
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.